勘误：非瓣膜性心房颤动中依度沙班和利伐沙班血浆浓度监测给药的安全性和有效性再评估：关于标签内和标签外给药的观察。
CORRIGENDUM: Safety and Efficacy Re-Evaluation of Edoxaban and Rivaroxaban Dosing With Plasma Concentration Monitoring in Non-Valvular Atrial Fibrillation: With Observations of On-Label and Off-Label Dosing.
作者信息
Suwa Michihiro, Nohara Yuki, Morii Isao, Kino Masaya
出版信息
Circ Rep. 2023 Sep 8;5(9):369. doi: 10.1253/circrep.CR-66-0012.
Abstract
[This corrects the article DOI: 10.1253/circrep.CR-22-0076.].
摘要
[本文更正了文章的数字对象标识符：10.1253/circrep.CR-22-0076。]
相似文献
1
CORRIGENDUM: Safety and Efficacy Re-Evaluation of Edoxaban and Rivaroxaban Dosing With Plasma Concentration Monitoring in Non-Valvular Atrial Fibrillation: With Observations of On-Label and Off-Label Dosing.勘误：非瓣膜性心房颤动中依度沙班和利伐沙班血浆浓度监测给药的安全性和有效性再评估：关于标签内和标签外给药的观察。
Circ Rep. 2023 Sep 8;5(9):369. doi: 10.1253/circrep.CR-66-0012.
2
Safety and Efficacy Re-Evaluation of Edoxaban and Rivaroxaban Dosing With Plasma Concentration Monitoring in Non-Valvular Atrial Fibrillation: With Observations of On-Label and Off-Label Dosing.依度沙班和利伐沙班在非瓣膜性心房颤动中基于血浆浓度监测的剂量安全性和有效性再评估：关于标签内和标签外给药的观察
Circ Rep. 2023 Mar 2;5(3):80-89. doi: 10.1253/circrep.CR-22-0076. eCollection 2023 Mar 10.
3
Rivaroxaban or Apixaban for Non-Valvular Atrial Fibrillation - Efficacy and Safety of Off-Label Under-Dosing According to Plasma Concentration.利伐沙班或阿哌沙班用于非瓣膜性心房颤动 - 根据血浆浓度的标签外低剂量使用的疗效和安全性。
Circ J. 2019 Apr 25;83(5):991-999. doi: 10.1253/circj.CJ-18-1282. Epub 2019 Mar 27.
4
Direct Oral Anticoagulant (DOAC) Dosing in Patients with Non-valvular Atrial Fibrillation (NVAF) in the United Kingdom: A Retrospective Cohort Study Using CPRD Gold Database.英国非瓣膜性心房颤动（NVAF）患者的直接口服抗凝剂（DOAC）剂量：一项使用CPRD Gold数据库的回顾性队列研究
Adv Ther. 2023 Feb;40(2):504-520. doi: 10.1007/s12325-022-02368-y. Epub 2022 Nov 18.
5
Relative efficacy and safety of non-Vitamin K oral anticoagulants for non-valvular atrial fibrillation: Network meta-analysis comparing apixaban, dabigatran, rivaroxaban and edoxaban in three patient subgroups.非维生素K口服抗凝药用于非瓣膜性心房颤动的相对疗效和安全性：在三个患者亚组中比较阿哌沙班、达比加群、利伐沙班和依度沙班的网状Meta分析
Int J Cardiol. 2016 Feb 1;204:88-94. doi: 10.1016/j.ijcard.2015.11.084. Epub 2015 Nov 17.
6
Comparison of Once-Daily Administration of Edoxaban and Rivaroxaban in Asian Patients with Atrial Fibrillation.亚洲心房颤动患者每日一次服用依度沙班和利伐沙班的比较。
Sci Rep. 2019 Apr 30;9(1):6690. doi: 10.1038/s41598-019-43224-4.
7
Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. An indirect comparison analysis.依度沙班与达比加群、利伐沙班及阿哌沙班相比在预防心房颤动患者卒中方面的疗效和安全性：一项间接比较分析
Thromb Haemost. 2014 May 5;111(5):981-8. doi: 10.1160/TH14-02-0118. Epub 2014 Feb 28.
8
Off-label dosing of non-vitamin K antagonist oral anticoagulants and clinical outcomes in Asian patients with atrial fibrillation.亚洲房颤患者非维生素K拮抗剂口服抗凝药的超说明书用药剂量与临床结局
Heart Rhythm. 2020 Dec;17(12):2102-2110. doi: 10.1016/j.hrthm.2020.07.022. Epub 2020 Jul 20.
9
Low-Dose Rivaroxaban and Risks of Adverse Events in Patients With Atrial Fibrillation.低剂量利伐沙班与房颤患者不良事件风险。
Stroke. 2019 Sep;50(9):2574-2577. doi: 10.1161/STROKEAHA.119.025623. Epub 2019 Jul 10.
10
Real-world evidence comparing oral anticoagulants in non-valvular atrial fibrillation: a systematic review and network meta-analysis.真实世界证据比较非瓣膜性心房颤动的口服抗凝药物：系统评价和网络荟萃分析。
Future Cardiol. 2022 May;18(5):393-405. doi: 10.2217/fca-2021-0120. Epub 2022 Apr 1.
Zotero 插件